Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EBIT (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed EBIT for 15 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 16.22% to -$2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.7 million, a 42.32% increase, with the full-year FY2025 number at -$2.9 million, down 82.09% from a year prior.
  • EBIT was -$2.0 million for Q4 2025 at Aytu Biopharma, down from -$1.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $3.1 million in Q4 2023 to a low of -$53.4 million in Q1 2022.
  • A 5-year average of -$8.4 million and a median of -$2.0 million in 2025 define the central range for EBIT.
  • Peak YoY movement for EBIT: plummeted 2518.09% in 2024, then soared 251.6% in 2025.
  • Aytu Biopharma's EBIT stood at -$11.3 million in 2021, then soared by 39.85% to -$6.8 million in 2022, then surged by 146.31% to $3.1 million in 2023, then tumbled by 153.88% to -$1.7 million in 2024, then fell by 16.22% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EBIT are -$2.0 million (Q4 2025), -$1.5 million (Q3 2025), and -$2.7 million (Q2 2025).